{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:29:02Z","timestamp":1794857342559,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"7925","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The efficacy of adoptive T cell therapies for cancer treatment can be limited by suppressive signals from both extrinsic factors and intrinsic inhibitory checkpoints\n                    <jats:sup>1,2<\/jats:sup>\n                    . Targeted gene editing has the potential to overcome these limitations and enhance T cell therapeutic function\n                    <jats:sup>3\u201310<\/jats:sup>\n                    . Here we performed multiple genome-wide CRISPR knock-out screens under different immunosuppressive conditions to identify genes that can be targeted to prevent T cell dysfunction. These screens converged on RASA2, a RAS GTPase-activating protein (RasGAP) that we identify as a signalling checkpoint in human T cells, which is downregulated upon acute T cell receptor stimulation\u00a0and\u00a0can increase gradually with chronic antigen exposure. RASA2 ablation enhanced MAPK signalling and chimeric antigen receptor (CAR) T cell cytolytic activity in response to target antigen. Repeated tumour antigen stimulations in vitro revealed that RASA2-deficient T cells show increased activation, cytokine production and metabolic activity compared with control cells, and show a marked advantage in persistent cancer cell killing. RASA2-knockout CAR T cells had a competitive fitness advantage over control cells in the\u00a0bone marrow in a mouse model of leukaemia. Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumours. Together, our findings highlight RASA2 as a promising target to enhance both persistence and effector function in T cell therapies for cancer treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41586-022-05126-w","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T12:04:14Z","timestamp":1661342654000},"page":"174-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":262,"title":["RASA2 ablation in T cells boosts antigen sensitivity and long-term function"],"prefix":"10.1038","volume":"609","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9410-7148","authenticated-orcid":false,"given":"Julia","family":"Carnevale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-0128","authenticated-orcid":false,"given":"Eric","family":"Shifrut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3185-8646","authenticated-orcid":false,"given":"Nupura","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Nyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5770-4744","authenticated-orcid":false,"given":"Franziska","family":"Blaeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3611-2621","authenticated-orcid":false,"given":"Yan Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-1511","authenticated-orcid":false,"given":"Sagar P.","family":"Bapat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5900-3060","authenticated-orcid":false,"given":"Morgan E.","family":"Diolaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2919-5943","authenticated-orcid":false,"given":"Patrick","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Vedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-6158","authenticated-orcid":false,"given":"Julia","family":"Belk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-8767","authenticated-orcid":false,"given":"Bence","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Bachl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Allo","family":"Anido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Prinzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Iba\u00f1ez-Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Haydar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Luetke-Eversloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelys","family":"Born-Bony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bindu","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2395-8479","authenticated-orcid":false,"given":"Scott","family":"Kogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8517-9681","authenticated-orcid":false,"given":"Tobias","family":"Feuchtinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-9920","authenticated-orcid":false,"given":"Hideho","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-537X","authenticated-orcid":false,"given":"Ansuman T.","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-1773","authenticated-orcid":false,"given":"Kevin","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-1190","authenticated-orcid":false,"given":"Justin","family":"Eyquem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-0644","authenticated-orcid":false,"given":"Giedre","family":"Krenciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-7878","authenticated-orcid":false,"given":"Alan","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-5776","authenticated-orcid":false,"given":"Alexander","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"key":"5126_CR1","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak, A. D., June, C. H. & Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566\u2013581 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"5126_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell 31, 311\u2013325 (2017).","journal-title":"Cancer Cell"},{"key":"5126_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471\u2013476 (2019).","journal-title":"Nature"},{"key":"5126_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/srep20070","volume":"6","author":"S Su","year":"2016","unstructured":"Su, S. et al. CRISPR\u2013Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep. 6, 20070 (2016).","journal-title":"Sci Rep."},{"key":"5126_CR5","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"5126_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp, L. J. et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 7, 737 (2017).","journal-title":"Sci Rep."},{"key":"5126_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"5126_CR8","doi-asserted-by":"publisher","first-page":"E4051","DOI":"10.1073\/pnas.1801340115","volume":"115","author":"W Shang","year":"2018","unstructured":"Shang, W. et al. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. Proc. Natl Acad. Sci. USA 115, E4051\u2013E4060 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5126_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2019.07.044","volume":"178","author":"MB Dong","year":"2019","unstructured":"Dong, M. B. et al. Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells. Cell 178, 1189\u20131204.e23 (2019).","journal-title":"Cell"},{"key":"5126_CR10","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2021.02.019","volume":"184","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262\u20131280.e22 (2021).","journal-title":"Cell"},{"key":"5126_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies, M. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541\u2013550 (2018).","journal-title":"Nat. Med."},{"key":"5126_CR12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana, S. A. et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat. Immunol. 21, 1022\u20131033 (2020).","journal-title":"Nat. Immunol."},{"key":"5126_CR13","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut, E. et al. Genome-wide CRISPR Screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958\u20131971.e15 (2018).","journal-title":"Cell"},{"key":"5126_CR14","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","volume":"168","author":"WA Lim","year":"2017","unstructured":"Lim, W. A. & June, C. H. The principles of engineering immune cells to treat cancer. Cell 168, 724\u2013740 (2017).","journal-title":"Cell"},{"key":"5126_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","volume":"22","author":"MV Sitkovsky","year":"2004","unstructured":"Sitkovsky, M. V. et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657\u2013682 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"5126_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"5126_CR17","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"5126_CR18","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","volume":"45","author":"G Plitas","year":"2016","unstructured":"Plitas, G. et al. Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45, 1122\u20131134 (2016).","journal-title":"Immunity"},{"key":"5126_CR19","doi-asserted-by":"publisher","unstructured":"DepMap 22Q1 Public. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.19139906.V1 (2022).","DOI":"10.6084\/M9.FIGSHARE.19139906.V1"},{"key":"5126_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","volume":"175","author":"BJ Schmiedel","year":"2018","unstructured":"Schmiedel, B. J. et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell 175, 1701\u20131715.e16 (2018).","journal-title":"Cell"},{"key":"5126_CR21","doi-asserted-by":"publisher","first-page":"e0252424","DOI":"10.1371\/journal.pone.0252424","volume":"16","author":"G Vasiukov","year":"2021","unstructured":"Vasiukov, G. et al. Adenosine\/TGF\u03b2 axis in regulation of mammary fibroblast functions. PLoS ONE 16, e0252424 (2021).","journal-title":"PLoS ONE"},{"key":"5126_CR22","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/eji.201141512","volume":"41","author":"FS Regateiro","year":"2011","unstructured":"Regateiro, F. S. et al. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-\u03b2. Eur. J. Immunol. 41, 2955\u20132965 (2011).","journal-title":"Eur. J. Immunol."},{"key":"5126_CR23","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/eji.201747124","volume":"47","author":"R Schoppmeyer","year":"2017","unstructured":"Schoppmeyer, R. et al. Human profilin 1 is a negative regulator of CTL mediated cell-killing and migration. Eur. J. Immunol. 47, 1562\u20131572 (2017).","journal-title":"Eur. J. Immunol."},{"key":"5126_CR24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.molcel.2011.11.023","volume":"45","author":"J-Y Chen","year":"2012","unstructured":"Chen, J.-Y., Lin, J.-R., Cimprich, K. A. & Meyer, T. A two-dimensional ERK\u2013AKT signaling code for an NGF-triggered cell-fate decision. Mol. Cell 45, 196\u2013209 (2012).","journal-title":"Mol. Cell"},{"key":"5126_CR25","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/ng.3427","volume":"47","author":"R Arafeh","year":"2015","unstructured":"Arafeh, R. et al. Recurrent inactivating RASA2 mutations in melanoma. Nat. Genet. 47, 1408\u20131410 (2015).","journal-title":"Nat. Genet."},{"key":"5126_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S1074-7613(02)00451-X","volume":"17","author":"JJ Priatel","year":"2002","unstructured":"Priatel, J. J., Teh, S.-J., Dower, N. A., Stone, J. C. & Teh, H.-S. RasGRP1 transduces low-grade TCR signals which are critical for T cell development, homeostasis, and differentiation. Immunity 17, 617\u2013627 (2002).","journal-title":"Immunity"},{"key":"5126_CR27","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1073\/pnas.0400782101","volume":"101","author":"AI Su","year":"2004","unstructured":"Su, A. I. et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl Acad. Sci. USA 101, 6062\u20136067 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5126_CR28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.it.2013.02.004","volume":"34","author":"RL Kortum","year":"2013","unstructured":"Kortum, R. L., Rouquette-Jazdanian, A. K. & Samelson, L. E. Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells. Trends Immunol. 34, 259\u2013268 (2013).","journal-title":"Trends Immunol."},{"key":"5126_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0092-8674(02)00767-5","volume":"109","author":"F Maci\u00e1n","year":"2002","unstructured":"Maci\u00e1n, F. et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 109, 719\u2013731 (2002).","journal-title":"Cell"},{"key":"5126_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-018-4718-6","volume":"19","author":"L Gioia","year":"2018","unstructured":"Gioia, L., Siddique, A., Head, S. R., Salomon, D. R. & Su, A. I. A genome-wide survey of mutations in the Jurkat cell line. BMC Genomics 19, 334 (2018).","journal-title":"BMC Genomics"},{"key":"5126_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"5126_CR32","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"5126_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"5126_CR34","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ccr.2006.10.003","volume":"10","author":"S Courtois-Cox","year":"2006","unstructured":"Courtois-Cox, S. et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459\u2013472 (2006).","journal-title":"Cancer Cell"},{"key":"5126_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.cmet.2015.07.020","volume":"22","author":"F Baixauli","year":"2015","unstructured":"Baixauli, F. et al. Mitochondrial respiration controls lysosomal function during inflammatory T cell responses. Cell Metab. 22, 485\u2013498 (2015).","journal-title":"Cell Metab."},{"key":"5126_CR36","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00262-016-1851-4","volume":"65","author":"L Chaudhuri","year":"2016","unstructured":"Chaudhuri, L., Srivastava, R. K., Kos, F. & Shrikant, P. A. Uncoupling protein 2 regulates metabolic reprogramming and fate of antigen-stimulated CD8+ T cells. Cancer Immunol. Immunother. 65, 869\u2013874 (2016).","journal-title":"Cancer Immunol. Immunother."},{"key":"5126_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman, N. M., Boothby, M. R. & Chi, H. Metabolic coordination of T cell quiescence and activation. Nat. Rev. Immunol. 20, 55\u201370 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"5126_CR38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nature22367","volume":"545","author":"M Philip","year":"2017","unstructured":"Philip, M. et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature 545, 452\u2013456 (2017).","journal-title":"Nature"},{"key":"5126_CR39","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.aaf2807","volume":"354","author":"KE Pauken","year":"2016","unstructured":"Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160\u20131165 (2016).","journal-title":"Science"},{"key":"5126_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"5126_CR41","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41591-018-0045-3","volume":"24","author":"X Guo","year":"2018","unstructured":"Guo, X. et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat. Med. 24, 978\u2013985 (2018).","journal-title":"Nat. Med."},{"key":"5126_CR42","doi-asserted-by":"publisher","first-page":"eabj4008","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).","journal-title":"Science"},{"key":"5126_CR43","doi-asserted-by":"publisher","first-page":"e1005177","DOI":"10.1371\/journal.ppat.1005177","volume":"11","author":"PK Gupta","year":"2015","unstructured":"Gupta, P. K. et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 11, e1005177 (2015).","journal-title":"PLoS Pathog."},{"key":"5126_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","volume":"45","author":"NE Scharping","year":"2016","unstructured":"Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 374\u2013388 (2016).","journal-title":"Immunity"},{"key":"5126_CR45","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","volume":"559","author":"TL Roth","year":"2018","unstructured":"Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405\u2013409 (2018).","journal-title":"Nature"},{"key":"5126_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem, J. et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543, 113\u2013117 (2017).","journal-title":"Nature"},{"key":"5126_CR47","doi-asserted-by":"publisher","first-page":"e136093","DOI":"10.1172\/jci.insight.136093","volume":"5","author":"B Prinzing","year":"2020","unstructured":"Prinzing, B. et al. MyD88\/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight 5, e136093 (2020).","journal-title":"JCI Insight"},{"key":"5126_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.omtm.2018.01.009","volume":"9","author":"Z Yi","year":"2018","unstructured":"Yi, Z., Prinzing, B. L., Cao, F., Gottschalk, S. & Krenciute, G. Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma. Mol. Ther. Methods Clin. Dev. 9, 70\u201380 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"5126_CR49","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0960-9822(99)80116-X","volume":"9","author":"PJ Lockyer","year":"1999","unstructured":"Lockyer, P. J. et al. Identification of the ras GTPase-activating protein GAP1(m) as a phosphatidylinositol-3,4,5-trisphosphate-binding protein in vivo. Curr. Biol. 9, 265\u2013268 (1999).","journal-title":"Curr. Biol."},{"key":"5126_CR50","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","volume":"185","author":"I Zhu","year":"2022","unstructured":"Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431\u20131443.e16 (2022).","journal-title":"Cell"},{"key":"5126_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR\u2013Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"5126_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"5126_CR53","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1126\/science.1546329","volume":"255","author":"RA Henderson","year":"1992","unstructured":"Henderson, R. A. et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 255, 1264\u20131266 (1992).","journal-title":"Science"},{"key":"5126_CR54","doi-asserted-by":"publisher","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten, A. et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci. Transl. Med. 13, eabd8836 (2021).","journal-title":"Sci. Transl. Med."},{"key":"5126_CR55","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-020-2246-4","volume":"582","author":"JT Cortez","year":"2020","unstructured":"Cortez, J. T. et al. CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature 582, 416\u2013420 (2020).","journal-title":"Nature"},{"key":"5126_CR56","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"5126_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"5126_CR58","doi-asserted-by":"publisher","unstructured":"Korotkevich, G. et al. Fast gene set enrichment analysis. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/060012 (2021).","DOI":"10.1101\/060012"},{"key":"5126_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst"},{"key":"5126_CR60","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12859-021-04130-7","volume":"22","author":"HE Miller","year":"2021","unstructured":"Miller, H. E. & Bishop, A. J. R. Correlation AnalyzeR: functional predictions from gene co-expression correlations. BMC Bioinf. 22, 206 (2021).","journal-title":"BMC Bioinf."},{"key":"5126_CR61","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"5126_CR62","doi-asserted-by":"publisher","first-page":"eabh0272","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).","journal-title":"Sci. Transl. Med."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05126-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05126-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:04:32Z","timestamp":1668711872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-022-05126-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":62,"journal-issue":{"issue":"7925","published-print":{"date-parts":[[2022,9,1]]}},"alternative-id":["5126"],"URL":"https:\/\/doi.org\/10.1038\/s41586-022-05126-w","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742292928.793597168","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,24]]},"assertion":[{"value":"31 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E. is a compensated co-founder at Mnemo Therapeutics, a compensated scientific advisor to Cytovia Therapeutics, owns stocks in Mnemo Therapeutica and Cytovia Therapeutics and has received a consulting fee from Casdin Capital. The Eyquem laboratory has received research support from Cytovia Therapeutic and Takeda. J.E. is a holder of patents pertaining to but not resulting from this work. A.A. is a co-founder of Tango Therapeutics, Azkarra Therapeutics, Ovibio Corporation and Kytarro, a member of the boards of Cytomx and Cambridge Science Corporation, a member of the scientific advisory boards of Genentech, GLAdiator, Circle, Bluestar, Earli, Ambagon, Phoenix Molecular Designs and Trial Library, a consultant for SPARC, ProLynx and GSK, and a recipient of grant or research support from SPARC and AstraZeneca, and holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefited financially (and may do so in the future).\u00a0A.M. is a cofounder of Arsenal Biosciences, Spotlight Therapeutics and Survey Genomics, serves on the boards of directors at Spotlight Therapeutics and Survey Genomics, is board observer (and former member of the board of directors) at Arsenal Biosciences, is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics and NewLimit, owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, and Merck, and has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ. The Marson laboratory has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead and Anthem. S.G. has a consulting agreement with Tessa Therapeutics, and is a compensated DSMB member of Immatics, and has received honoraria from Tidal, Catamaran Bio and Novartis within the last 2 years. The Gottschalk laboratory has received research support from Tessa Therapeutics. A.T.S. is a scientific founder of Immunai and founder of Cartography Biosciences and receives research funding from Arsenal Biosciences, Allogene Therapeutics and Merck Research Laboratories. H.O. has been a compensated consultant within the last 2 years for Bristol-Myers Squibb, Alexion Pharmaceuticals, Amal Therapeutics, Servier Pharmaceuticals, Neuvogen and Eureka Therapeutics. J.C., E.S., A.A. and A.M. are listed as inventors on a world\u00a0patent application (WO2020014235A1) related to this work, <i>Gene Targets for T-cell-Based Immunotherapy<\/i>, which has been licensed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}